Objective: The aim of this study was to assess the real-world safety profile of medical devices used in focal prostate cancer treatment utilizing the Manufacturer and User Facility Device Experience (MAUDE) database. Methods: The MAUDE database was searched for reports on high-intensity focused ultrasound (HIFU), cryoablation, laser ablation, and irreversible electroporation (IRE) devices used in prostate cancer treatment from 1993 to 2023. Adverse events were identified and categorized. Results: We identified 175 reports for HIFU, 1362 for cryoablation, 615 for laser ablation, and 135 for IRE devices, with 28, 284, 126, and 2 respective reports, directly related to prostate cancer treatment. The aggregated data revealed the majority of complications were minor, with 82.5% (n = 363 out of 440 total complications) classified as Clavien-Dindo grade 1 or 2. Common minor complications included erectile dysfunction and urinary retention. Severe complications such as rectal fistulas were noted in HIFU and IRE treatments, along with singular mortality due to pulmonary embolism in cryoablation. Conclusions: Our analyses from MAUDE reveal that devices used in focal therapy for prostate cancer are predominantly associated with minor complications, underscoring their overall real-world safety profile. However, the occurrence of severe adverse events emphasizes the critical importance of rigorous patient selection and meticulous procedural planning. These findings provide valuable insights into the safety profile of focal therapy devices and contribute to the growing body of evidence on their use in prostate cancer treatment.
Journal of endourology. 2024 Oct 24 [Epub ahead of print]
Zhiyu Qian, Boyuan Xiao, Filippo Dagnino, Julia Feldman, Jonathan Song, Hanna Zurl, Daniel Stelzl, Stephan Korn, Leonardo Reis, Caroline M Moore, Quoc-Dien Trinh, Alexander P Cole
Department of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA., Department of Urology and Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, London, United Kingdom.